


CLAIMS

1. The use of a composition essentially consisting of at least one soluble form of HLA-G and of at least one pharmaceutically acceptable vehicle, for preparing a medicinal product for treating inflammatory pathological skin conditions.
2. The use as claimed in claim 1, characterized in that said soluble form of HLA-G is selected from the group consisting of the soluble isoforms of HLA-G comprising at least the $\alpha 1$ extracellular domain and the solubilized forms of HLA-G1, HLA-G2, HLA-G3 or HLA-G4.
-  The use as claimed in claim 1 or claim 2, characterized in that said composition comprises between 0.1 and 5 $\mu\text{g/ml}$, preferably between 0.5 and 2.5 $\mu\text{g/ml}$, of soluble form of HLA-G.
4. A method for preparing a soluble HLA-G, characterized in that it comprises the following steps:
- coinfecting insect cells with a baculovirus containing the $\beta_2\text{M}$ cDNA and another baculovirus containing the α chain of a soluble isoform of HLA-G;
 - culturing the transfected insect cells, and
 - harvesting the supernatants and purifying the soluble isoform of HLA-G expressed.
5. The method as claimed in claim 4, characterized in that said soluble isoform of HLA-G is purified using an antibody specific for the soluble isoforms of HLA-G.

6. The method as claimed in claim 5, characterized in that said antibody is obtained by immunizing nonhuman mammals, in particular rabbits, with an immunogenic peptide of SEQ ID NO:1 coupled to the KLH carrier protein.
- 5
7. A soluble anti-HLA-G antibody, characterized in that it is obtained by immunizing nonhuman mammals, in particular rabbits, with an immunogenic peptide consisting of a 21 amino acid synthetic peptide of SEQ ID No:1 coupled to the KLH carrier protein.
- 10